Asset profile
CardiolRx · Cardiol Therapeutics (CRDL)
- Indication
- recurrent pericarditis
- Also known as
- CardiolRx™
Company
CRDLCardiol Therapeutics
CRDLCardiol TherapeuticsCardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, wh…
On the calendar
Nothing scheduled in this window.
Timeline
Newest first.
Registered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT05494788 | Phase 2 | Completed | Jun 15, 2024 | 27 | 8 of 8 sites in the United States |
| NCT06708299 | Phase 3 | Recruiting | Sep 21, 2026 | 110 | 21 of 27 sites in the United States |
| NCT05180240 | Phase 2 | Completed | Jan 31, 2025 | 109 | 6 of 37 sites in the United States |